AIM
CBIO

Acrospire Investment Management’s Crescent Biopharma CBIO Stock Holding History

Acrospire Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4
Closed -$3K – 2289
2016
Q3 		$3K Sell
4
-33
-89% -$25.3K ﹤0.01% 1884
2016
Q2 		$27K Buy
+37
New +$25.5K 0.02% 1428

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Acrospire Investment Management's CBIO Position: Q4 2016 in Review

Acrospire Investment Management sold out of Crescent Biopharma (CBIO) in Q4 2016, closing a stake of 4 shares — an estimated $3K sold.

Acrospire Investment Management first reported a position in CBIO in Q2 2016 and held it in 2 quarters. The position peaked at $27K in Q2 2016. 50 funds tracked by Wall St. Rank hold CBIO as of Q4 2016.

  • Acrospire Investment Management reported no remaining Crescent Biopharma position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 4 Crescent Biopharma shares in Q4 2016, an estimated $3K.
  • Acrospire Investment Management first reported a position in Crescent Biopharma in Q2 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Crescent Biopharma position peaked at $27K in Q2 2016.
  • 50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.